Tech Company Inital Public Offerings
Kronos Bio IPO
Kronos Bio, based in San Mateo, debuted as a public company on 10/8/2020.
Transaction Overview
Company Name
Announced On
10/8/2020
Transaction Type
IPO
Amount
$250,800,000
Proceeds Purpose
Management says it will use the net proceeds from the IPO as follows:approximately $80.0 million to $90.0 million to fund our planned registrational Phase 2/3 clinical trial of ENTO in combination with IC in AML patients with NPM1 mutations, which includes a $29.0 million milestone payment by us to Gilead upon the initiation of this trial;approximately $20.0 million to $30.0 million to fund our planned Phase 1/2 clinical trial of KB-0742 for the treatment of advanced solid tumors; andthe remainder for additional development activities for our SYK and CDK9 programs, continued discovery and preclinical development of additional product candidates, as well as headcount costs, working capital and other general corporate purposes.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
1300 So. El Camino Real 300
San Mateo, CA 94402
USA
San Mateo, CA 94402
USA
Phone
Undisclosed
Website
Email Address
Overview
Kronos Bio (Nasdaq: KRON) is dedicated to the research and development of first-in-class therapies that modulate historically recalcitrant cancer targets.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Norbert Bischofberger
Chief Financial Officer
Yasir Al-Wakeel
Chief Marketing Officer
Jorge DiMartino
Chief Operating Officer
Barbara Kosacz
Chief Scientific Officer
Christopher Dinsmore
Vice President
Christopher Lee
Vice President
Charles Lin
Vice President
Douglas Saffran
Vice President
Wes Trotter
VP - Bus. Development
Philip Gutry
VP - Operations
Zung To
VP - Regulatory Affairs
Jennifer Nicholson
Browse more venture capital transactions:
Prev: 10/8/2020: Avail Medsystems venture capital transaction
Next: 10/8/2020: Cerebral venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from company press releases and news coverage. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs